Does the media refer more to RYTM or KLRA?

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Kailera Therapeutics. MarketBeat recorded 11 mentions for Rhythm Pharmaceuticals and 6 mentions for Kailera Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.45 beat Kailera Therapeutics' score of 0.07 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SRRK or KLRA?

Scholar Rock is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Is SRRK or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Kailera Therapeutics N/A N/A N/A

Does the media prefer SRRK or KLRA?

In the previous week, Scholar Rock had 10 more articles in the media than Kailera Therapeutics. MarketBeat recorded 16 mentions for Scholar Rock and 6 mentions for Kailera Therapeutics. Scholar Rock's average media sentiment score of 0.72 beat Kailera Therapeutics' score of 0.07 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CGON or KLRA?

In the previous week, CG Oncology and CG Oncology both had 6 articles in the media. CG Oncology's average media sentiment score of 0.79 beat Kailera Therapeutics' score of 0.07 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KLRA or MIRM?

In the previous week, Kailera Therapeutics and Kailera Therapeutics both had 6 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.56 beat Kailera Therapeutics' score of 0.07 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TVTX or KLRA?

In the previous week, Travere Therapeutics had 37 more articles in the media than Kailera Therapeutics. MarketBeat recorded 43 mentions for Travere Therapeutics and 6 mentions for Kailera Therapeutics. Travere Therapeutics' average media sentiment score of 0.30 beat Kailera Therapeutics' score of 0.07 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 16 Very Positive mention(s) 10 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Kailera Therapeutics (KLRA) Competitors

$12.79 +0.80 (+6.67%)

As of 09/22/2026 04:00 PM Eastern

Compare

KLRA vs. RYTM, SRRK, CGON, MIRM, and TVTX

Should you buy Kailera Therapeutics stock or one of its competitors? Kailera Therapeutics's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kailera Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Kailera Therapeutics. MarketBeat recorded 11 mentions for Rhythm Pharmaceuticals and 6 mentions for Kailera Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.45 beat Kailera Therapeutics' score of 0.07 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kailera Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Kailera Therapeutics' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Kailera Therapeutics	N/A	N/A	N/A

Kailera Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	35.85	-$196.54M	-$3.11	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Rhythm Pharmaceuticals currently has a consensus price target of $140.67, suggesting a potential upside of 41.70%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 234.25%. Given Kailera Therapeutics' higher possible upside, analysts plainly believe Kailera Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Kailera Therapeutics beats Rhythm Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Kailera Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Scholar Rock is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Kailera Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Kailera Therapeutics	N/A	N/A	N/A

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Scholar Rock presently has a consensus price target of $66.69, suggesting a potential upside of 30.27%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 234.25%. Given Kailera Therapeutics' higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Scholar Rock had 10 more articles in the media than Kailera Therapeutics. MarketBeat recorded 16 mentions for Scholar Rock and 6 mentions for Kailera Therapeutics. Scholar Rock's average media sentiment score of 0.72 beat Kailera Therapeutics' score of 0.07 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Scholar Rock beats Kailera Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Kailera Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, CG Oncology and CG Oncology both had 6 articles in the media. CG Oncology's average media sentiment score of 0.79 beat Kailera Therapeutics' score of 0.07 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kailera Therapeutics has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Kailera Therapeutics' return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Kailera Therapeutics	N/A	N/A	N/A

Kailera Therapeutics has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,705.66	-$160.99M	-$2.69	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

CG Oncology currently has a consensus price target of $87.78, indicating a potential upside of 12.91%. Kailera Therapeutics has a consensus price target of $42.75, indicating a potential upside of 234.25%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Kailera Therapeutics beats CG Oncology on 8 of the 14 factors compared between the two stocks.

How does Kailera Therapeutics compare to Mirum Pharmaceuticals?

Kailera Therapeutics (NASDAQ:KLRA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

In the previous week, Kailera Therapeutics and Kailera Therapeutics both had 6 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.56 beat Kailera Therapeutics' score of 0.07 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 234.25%. Mirum Pharmaceuticals has a consensus target price of $137.31, suggesting a potential upside of 50.25%. Given Kailera Therapeutics' higher possible upside, analysts clearly believe Kailera Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has higher revenue and earnings than Kailera Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Mirum Pharmaceuticals	$521.31M	11.38	-$23.36M	-$14.55	N/A

Kailera Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Kailera Therapeutics' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Mirum Pharmaceuticals beats Kailera Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Kailera Therapeutics compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Kailera Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Kailera Therapeutics' return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Kailera Therapeutics	N/A	N/A	N/A

Travere Therapeutics currently has a consensus target price of $68.10, suggesting a potential upside of 12.97%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 234.25%. Given Kailera Therapeutics' higher probable upside, analysts clearly believe Kailera Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Travere Therapeutics had 37 more articles in the media than Kailera Therapeutics. MarketBeat recorded 43 mentions for Travere Therapeutics and 6 mentions for Kailera Therapeutics. Travere Therapeutics' average media sentiment score of 0.30 beat Kailera Therapeutics' score of 0.07 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	16 Very Positive mention(s)	10 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Travere Therapeutics has higher revenue and earnings than Kailera Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	11.58	-$25.55M	-$0.46	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Summary

Travere Therapeutics and Kailera Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Kailera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRA vs. The Competition

Export

Metric	Kailera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.55B	$3.91B	$7.27B	$13.25B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	0.00	14.43	274.31	25.86
Price / Sales	N/A	1,389.70	639.21	91.22
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	N/A	15.80	10.69	6.42
Net Income	-$148.96M	-$22.82M	$3.49B	$360.08M
7 Day Performance	0.71%	2.57%	2.58%	2.79%
1 Month Performance	-25.51%	-3.46%	-1.80%	-2.48%
1 Year Performance	N/A	39.75%	18.64%	7.15%

Kailera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRA Kailera Therapeutics	3.1843 of 5 stars	$12.79 +6.7%	$42.75 +234.2%	N/A	$1.55B	N/A	N/A	145	Gap Up
RYTM Rhythm Pharmaceuticals	2.8281 of 5 stars	$104.71 +2.5%	$141.12 +34.8%	+0.3%	$7.18B	$189.76M	N/A	414
SRRK Scholar Rock	3.6869 of 5 stars	$55.41 -0.5%	$58.77 +6.1%	+57.1%	$6.75B	N/A	N/A	289	Analyst Forecast Gap Down
CGON CG Oncology	2.5574 of 5 stars	$72.35 +0.5%	$87.78 +21.3%	+109.9%	$6.41B	$4.04M	N/A	142
MIRM Mirum Pharmaceuticals	2.886 of 5 stars	$98.22 -2.4%	$137.31 +39.8%	+23.6%	$6.38B	$521.31M	N/A	433

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRA) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kailera Therapeutics (KLRA) Competitors

KLRA vs. RYTM, SRRK, CGON, MIRM, and TVTX

How does Kailera Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Kailera Therapeutics compare to Scholar Rock?

Summary

How does Kailera Therapeutics compare to CG Oncology?

Summary

How does Kailera Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Kailera Therapeutics compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kailera Therapeutics (KLRA) Competitors

KLRA vs. RYTM, SRRK, CGON, MIRM, and TVTX

How does Kailera Therapeutics compare to Rhythm Pharmaceuticals?

Does the media refer more to RYTM or KLRA?

Is RYTM or KLRA more profitable?

Which has better valuation and earnings, RYTM or KLRA?

Do analysts recommend RYTM or KLRA?

Summary

How does Kailera Therapeutics compare to Scholar Rock?

Which has better earnings and valuation, SRRK or KLRA?

Is SRRK or KLRA more profitable?

Do insiders and institutionals hold more shares of SRRK or KLRA?

Do analysts prefer SRRK or KLRA?

Does the media prefer SRRK or KLRA?

Summary

How does Kailera Therapeutics compare to CG Oncology?

Does the media refer more to CGON or KLRA?

Do institutionals and insiders believe in CGON or KLRA?

Is CGON or KLRA more profitable?

Which has stronger valuation and earnings, CGON or KLRA?

Do analysts rate CGON or KLRA?

Summary

How does Kailera Therapeutics compare to Mirum Pharmaceuticals?

Does the media prefer KLRA or MIRM?

Do analysts prefer KLRA or MIRM?

Which has preferable earnings and valuation, KLRA or MIRM?

Is KLRA or MIRM more profitable?

Summary

How does Kailera Therapeutics compare to Travere Therapeutics?

Is TVTX or KLRA more profitable?

Do analysts prefer TVTX or KLRA?

Does the media refer more to TVTX or KLRA?

Which has higher earnings and valuation, TVTX or KLRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRA vs. The Competition

Kailera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools